CHEESE Italia - italiano - Ministero della Salute

cheese

wuhan gigaa optronics technology co., ltd - laser chirurgico a diodi

COVID-19 Vaccine (inactivated, adjuvanted) Valneva Unione Europea - italiano - EMA (European Medicines Agency)

covid-19 vaccine (inactivated, adjuvanted) valneva

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccini - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Xevudy Unione Europea - italiano - EMA (European Medicines Agency)

xevudy

glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - sieri immuni e immunoglobuline, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.

Xevudy Concentrato per soluzione per Infusione Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

xevudy concentrato per soluzione per infusione

glaxosmithkline ag - sotrovimabum - concentrato per soluzione per infusione - sotrovimabum 500 mg, histidinum, histidini hydrochloridum monohydricum, saccharum, polysorbatum 80, methioninum, aqua ad iniectabile q.s. ad solutionem pro 8 ml. - behandlung von covid-19 - biotechnologika

Fluenz Tetra Nasenspray, Suspension Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

fluenz tetra nasenspray, suspension

astrazeneca ag - virus influenzae a (h1n1) vivus attenuatum (virus-stamm a/victoria/2570/2019 (h1n1)pdm09-like strain (a/victoria/1/2020, medi 340505)), virus influenzae a (h3n2) vivus attenuatum (virus-stamm a/darwin/9/2021 (h3n2)-like a/norway/16606/2021 (medi 355293)), virus influenzae b vivus attenuatum (virus-stamm b/austria/1359417/2021-like b/austria/1359417/2021 (medi 355293, victoria lineage)) - nasenspray, suspension - virus influenzae a (h1n1) vivus attenuatum (virus-stamm a/victoria/2570/2019 (h1n1)pdm09-like strain (a/victoria/1/2020, medi 340505)) 70 mio. ffu, virus influenzae a (h3n2) vivus attenuatum (virus-stamm a/darwin/9/2021 (h3n2)-like a/norway/16606/2021 (medi 355293)) 70 mio. ffu, virus influenzae b vivus attenuatum (virus-stamm b/austria/1359417/2021-like b/austria/1359417/2021 (medi 355293, victoria lineage)) 70 mio. ffu, virus influenzae b vivus attenuatum (virus-stamm b/phuket/3073/2013-like: b/phuket/3073/2013 (medi 306444, yamagata lineage)) 70 mio. ffu, saccharum, dikalii phosphas anhydricus, kalii dihydrogenophosphas, gelatina hydrolysata, arginini hydrochloridum, natrii hydrogenoglutamas monohydricus, aqua ad iniectabile q.s. ad suspensionem pro 0.2 ml. - aktive immunisierung gegen influenza für kinder und jugendliche im alter von 2-18 jahren - vaccini

Bimervax Unione Europea - italiano - EMA (European Medicines Agency)

bimervax

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vaccini - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Co-Valsartan Sandoz 80/12.5 Compresse rivestite con film Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

co-valsartan sandoz 80/12.5 compresse rivestite con film

sandoz pharmaceuticals ag - valsartanum, hydrochlorothiazidum - compresse rivestite con film - valsartanum 80 mg, hydrochlorothiazidum 12.5 mg, cellulosum microcristallinum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, Überzug: hypromellosum, talcum, macrogolum 8000, e 171, e 172 (rubrum), e 172 (flavum), pro compresso obducto. - hypertonie - synthetika

Co-Valsartan Sandoz 160/12.5 Compresse rivestite con film Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

co-valsartan sandoz 160/12.5 compresse rivestite con film

sandoz pharmaceuticals ag - valsartanum, hydrochlorothiazidum - compresse rivestite con film - valsartanum 160 mg, hydrochlorothiazidum 12.5 mg, cellulosum microcristallinum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, Überzug: hypromellosum, talcum, macrogolum 8000, e 171, e 172 (rubrum), pro compresso obducto. - hypertonie - synthetika

Co-Valsartan Sandoz 160/25 Compresse rivestite con film Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

co-valsartan sandoz 160/25 compresse rivestite con film

sandoz pharmaceuticals ag - valsartanum, hydrochlorothiazidum - compresse rivestite con film - valsartanum 160 mg, hydrochlorothiazidum 25 mg, cellulosum microcristallinum, crospovidonum, magnesii stearas, silica colloidalis anhydrica, Überzug: hypromellosum, talcum, macrogolum 4000, e 171, e 172 (nigrum), e 172 (rubrum), e 172 (flavum), pro compresso obducto. - hypertonie - synthetika

Edurant Unione Europea - italiano - EMA (European Medicines Agency)

edurant

janssen-cilag international n.v.    - rilpivirina cloridrato - infezioni da hiv - antivirali per uso sistemico - edurant, in associazione con altri medicinali antiretrovirali, è indicato per il trattamento del virus dell'immunodeficienza umana di tipo 1 (hiv‑1) infezione in pazienti treatment‑naïve antiretrovirale 12 anni di età ed oltre con una carica virale ≤ 100.000 hiv‑1 rna copie/ml. come con altri medicinali antiretrovirali, test di resistenza genotipica devono guidare l'uso di edurant.